Blackstone plots $4.5B+ life sciences fund — and they've already secured the bulk of it
More than a year ago Blackstone jumped into the deep end of life sciences investing by buying Clarus, a storied investor in the field with a reputation for gambling on late-stage drug development. A couple of high-profile bets later, we’ve just had a glimpse of Blackstone Life Sciences’ appetite.
The private equity giant has raised $3.44 billion for Blackstone Life Sciences Fund V, for which it’s targeting $4.58 billion in total, according to an SEC filing.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 72,900+ biopharma pros reading Endpoints daily — and it's free.